I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Shares of Vertex Pharmaceuticals (NASDAQ: VRTX ) have been very resilient in the last six ...

KING OF PRUSSIA, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, today announced it has completed a strategic investment in Kintsugi, a San Francisco-based, AI-native startup focused on automating sales tax compliance for small and mid-size businesses (SMBs). Terms of the agreement include a $15 million minority investment representing a 10 percent ownership interest, as well as IP sharing and a commerci ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Vertex (VERX) . This company, which is in the Zacks Internet - Software industry, shows potential for another earnings beat.This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 10.71%.For the most recent quarte ...

We expect Vertex Pharmaceuticals Incorporated (VRTX) to surpass expectations when it reports first-quarter 2025 results on May 5, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.82 billion, while the same for earnings is $4.22 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)Year to date, shares of Vertex have rallied 23.3% against the industry’s decline of 5.2%.Image Source: Zacks Investment ResearchFactors Shaping ...

Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-quarter report, expected to drop shortly on May 5, after market hours.Alyftrek and Journavx — The Two Big LaunchesAccording to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyf ...

KING OF PRUSSIA, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of the ca ...

KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), a global provider of indirect tax technology solutions, today announced the expansion of its Chief Strategy Office (CSO) with the addition of Christopher Hall and Kathya Capote Peimbert. Their extensive experience in e-invoicing, global tax compliance and ERP integration further reinforces Vertex's continued commitment to innovation and excellence, helping businesses navigate an increasingly compl ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.72%). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two recent new drug approv ...

Core Insights - Vertex Pharmaceuticals is experiencing positive momentum with its newly launched painkiller Journavx, which is gaining traction in both hospital and retail settings [2][3] - The drug is reportedly available on close to 90% of U.S. pharmacy shelves, indicating strong market penetration [2] - Vertex's 2025 revenue guidance is projected between $11.75 billion and $12 billion, primarily driven by cystic fibrosis therapies, with potential upside from Journavx and other therapies [3] Journavx Performance - Journavx has shown a strong start in the acute pain market, with coverage picking up faster than anticipated [3] - The drug is currently placed in Tier 3, but management emphasizes the overall value and positive anecdotal results from prescribing physicians and patients [3] Future Growth Potential - Two potential upside levers for Vertex's revenue in 2025 have been identified, with one already showing positive developments while the other is expected to take longer [3] - The company remains confident in its next-generation cystic fibrosis drug Alyftrek, despite challenges related to international intellectual property rights, particularly in Russia [4] Market Outlook - Vertex is expected to benefit from a rotation in the macro backdrop, supported by its high-quality profile and positive momentum in pain and gene therapy [4] - JPMorgan has reiterated its Overweight rating on Vertex, reflecting confidence in the company's growth prospects [5]

My previous investment thought on Vertex, Inc. (NASDAQ: VERX ) (published on 7th November) was a downgrade to a hold rating because I felt that the valuation was too high. I wouldn’t call thisI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. Ultimately, I aim to identif ...